Picture of Autolus Therapeutics logo

AUTL Autolus Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Autolus Therapeutics PLC expected to post a loss of 46 cents a share - Earnings Preview

* Autolus Therapeutics PLC  AUTL.OQ   AUTL.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
3. 
    * The London United Kingdom-based   company is expected to
report 
a 42.8% decrease in revenue to $135 thousand from $236 thousand
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Autolus
Therapeutics PLC
is for a loss of 46 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Autolus
Therapeutics PLC is $11​, above​ its last closing price
of $2.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.42       -0.42      -0.46     Missed  -9.5
 Mar. 31 2022  -0.49       -0.48      -0.41     Beat    14.8
 Dec. 31 2021  -0.53       -0.46      -0.51     Missed  -10.5​
 Sep. 30 2021  -0.52       -0.51      -0.47     Beat    7
 ​​Jun.        -0.50       -0.50      -0.47     Beat    5.8
 30 2021                                                
 Mar. 31 2021  -0.61       -0.60      -0.52     Beat    14​
 Dec. 31 2020  -0.78       -0.77      -0.83     Missed  -8.4
 Sep. 30 2020  -0.70       -0.71      -0.72     Missed  -1.9
 This summary was machine generated November 1 at 18:37 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Autolus Therapeutics

See all news